{
    "nct_id": "NCT04045613",
    "official_title": "An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations",
    "inclusion_criteria": "* Histologically-confirmed transitional cell carcinoma of the urothelium of the upper or lower urinary tract\n* Recurrent or progressing stage IV disease, or surgically unresectable, recurrent or progressing disease\n* Documented central FGFR genetic aberration (FGFR1, FGFR2, or FGFR3 mutations / short variants and rearrangements / fusions) (Note; Substudy 2 started with patients requiring an FGFR GA, but this requirement was removed from the protocol later on)\n* Measurable disease, as defined by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2\n* Adequate organ functions as indicated by Screening visit local laboratory values\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receipt of prior cancer treatment within specific interval periods\n* Concurrent evidence of any clinically significant corneal or retinal disorder\n* History of clinically significant cardiac disorders\n* Known CNS metastases\n* Concurrent uncontrolled or active infection with human immunodeficiency virus\n* Active hepatitis B or chronic hepatitis B without current antiviral therapy\n* Active hepatitis C\n* Active tuberculosis\n* Severe bacterial, fungal, viral and/or parasitic infections on therapeutic oral or IV medication at the time of first dose of study drug administration",
    "miscellaneous_criteria": ""
}